¼¼°èÀÇ ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå º¸°í¼­(2025³â)
Personalized Medicine Biomarkers Global Market Report 2025
»óǰÄÚµå : 1751070
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,521,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,426,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,330,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö ³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµÉ ¿¹Á¤ÀÔ´Ï´Ù. ½ÃÀü Á¾¾ç¿¡¼­ÀÇ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ÀÀ¿ë È®´ë, Ç¥Àû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÁÖ¸ñ Áõ°¡, °³ÀÎÈ­ Á¢±Ù¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼ö¿ä Áõ°¡, Á¤ºÎÀÇ Áö¿ø Á¤Ã¥°ú ÀÚ±Ý Á¦°ø¿¡ ÀÇÇÑ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿Çâ¿¡´Â ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°¿¡ À־ÀÇ ¸ÖƼ¿À¹Í½º ¾îÇÁ·ÎÄ¡ÀÇ Ã¤¿ë, ¸®Äûµå ¹ÙÀ̿ɽÿ¡ ±Ù°ÅÇÑ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °³¹ß, µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ÀÌ¿ëÀÇ È®´ë, ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö¿¡ À־ÀÇ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕ µî ¹ÙÀÌ¿À¸¶Ä¿ °ËÁõ¿¡ À־ÀÇ ½ÇÁ¦ Áõ°ÅÀÇ È®´ë µîÀÌ ÀÖ½À´Ï´Ù.

¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â °³ÀÎÈ­µÈ ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ »ó´çÇÑ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸¸¼º Áúȯ Áõ°¡´Â °Ç°­¿¡ ÇØ·Î¿î ¶óÀÌÇÁ ½ºÅ¸ÀÏ ¼±ÅÃ, ½Ä»ýȰ ±³¶õ, ¿îµ¿ ºÎÁ·, ³ôÀº ½ºÆ®·¹½º ¼öÁØÀÌ ÁÖ¿ä ¿øÀÎÀÔ´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿´Â °³ÀÎÀÇ À¯ÀüÀû ¹× ºÐÀÚÀû ÇÁ·ÎÇÊ¿¡ µû¶ó Ä¡·á¸¦ ¸ÂÃãÈ­ÇÏ¿© ÀÌ·¯ÇÑ »óŸ¦ °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ ¹ÙÀÌ¿À ¸¶Ä¿´Â °¡Àå È¿°úÀûÀÎ Ä¡·á¹ýÀ» È®ÀÎÇϰí Áúº´ÀÇ ÁøÇàÀ» ¿¹ÃøÇÏ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. º¸°Ç±â±¸(WHO)´Â 2050³â±îÁö »õ·Î¿î ¾Ï ȯÀÚ ¼ö°¡ 3,500¸¸¸íÀ» ³Ñ¾î¼³ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖÀ¸¸ç, 2022³â ´ëºñ 77% Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À ¸¶Ä¿ ½ÃÀåÀÇ ±â¾÷Àº Á¦Ç°ÀÇ ½Å·Ú¼ºÀ» ³ôÀÌ°í ½ÃÀå ¹üÀ§¸¦ È®´ëÇϰí ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϱâ À§ÇØ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ Ãëµæ¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. Illumina Inc.´Â ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç¿Í 2°³ÀÇ µ¿¹ÝÁø´ÜÁ¦¿¡ ´ëÇØ FDAÀÇ ½ÂÀÎÀ» ÃëµæÇß½À´Ï´Ù. ÀÌ Å×½ºÆ®´Â Â÷¼¼´ë ½ÃÄö½Ì(NGS) ±â¼úÀ» »ç¿ëÇÏ¿© ¾Ï¼¼Æ÷ÀÇ À¯ÀüÀÚ µ¹¿¬º¯À̸¦ ½Äº°ÇÏ¿© ÀÓ»óÀǰ¡ °³º° ¹ÙÀÌ¿À¸¶Ä¿¸¦ ±â¹ÝÀ¸·Î °¡Àå ÀûÇÕÇÑ Ä¡·á¹ýÀ» ¼±ÅÃÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. À̹ø ½ÂÀÎÀº ÇÁ¸®½ÃÀü Á¾¾ç¿¡ À־ÀÇ Áß¿äÇÑ ÀÌÁ¤Ç¥À̸ç, Ä¡·á ¼±ÅÃÀÇ ½ºÇǵå¿Í Á¤¹Ðµµ¸¦ Çâ»ó½ÃÄÑ, ¾Ï ȯÀÚ¿¡ ´ëÇÑ ¸ÂÃãÇü Ä¡·á¸¦ °­È­ÇÏ´Â °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, Äڷγª ÅÂ¿Í È¸º¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Personalized medicine biomarkers are specific biological indicators that customize medical treatments for individual patients based on their unique genetic, molecular, or physiological characteristics. These biomarkers help predict how a patient will respond to a particular drug, allowing healthcare providers to select the most effective and safest treatment options.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of biomarkers in personalized medicine include genomic, proteomic, metabolic, and other types. Genomic biomarkers refer to specific genes or genetic mutations that provide insights into how diseases develop and progress in individuals. These biomarkers are used for a variety of disease indications, such as oncology, neurology, diabetes, autoimmune diseases, cardiology, and more. They serve various purposes, including early detection or screening, diagnosis, treatment selection, and monitoring. Personalized medicine biomarkers are utilized by a range of end users, including hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic laboratories, and others.

The personalized medicine biomarkers market research report is one of a series of new reports from The Business Research Company that provides personalized medicine biomarkers market statistics, including personalized medicine biomarkers industry global market size, regional shares, competitors with a personalized medicine biomarkers market share, detailed personalized medicine biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the personalized medicine biomarkers industry. This personalized medicine biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The personalized medicine biomarkers market size has grown rapidly in recent years. It will grow from $22.85 billion in 2024 to $26.98 billion in 2025 at a compound annual growth rate (CAGR) of 18.0%. The growth during the historic period can be attributed to the increasing prevalence of chronic diseases, the rising adoption of companion diagnostics, growing investment in biomarker research, a heightened focus on early diagnosis and preventive healthcare, and regulatory support for biomarker-based therapies.

The personalized medicine biomarkers market size is expected to see rapid growth in the next few years. It will grow to $51.53 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth during the forecast period can be attributed to the expanding applications of biomarkers in precision oncology, rising demand for targeted therapies, a growing focus on early disease detection, increasing consumer demand for personalized approaches, and supportive government policies and funding. Key trends expected in the forecast period include the adoption of a multi-omics approach for biomarker identification, the development of liquid biopsy-based biomarkers, a growing use of digital biomarkers, the integration of AI and machine learning in biomarker discovery, and the expansion of real-world evidence in biomarker validation.

The growing prevalence of chronic diseases is expected to drive substantial growth in the personalized medicine biomarkers market. Chronic diseases are long-term conditions that develop gradually and persist for extended periods, often requiring ongoing medical care or affecting daily activities. The rise in chronic diseases is largely attributed to unhealthy lifestyle choices, poor diets, insufficient physical activity, and high stress levels. Personalized medicine biomarkers play a key role in managing these conditions by tailoring treatments based on individual genetic and molecular profiles. These biomarkers help identify the most effective therapies, predict disease progression, and minimize adverse effects. For example, the World Health Organization (WHO) predicts that by 2050, the number of new cancer cases will exceed 35 million, a 77% increase from 2022. This escalating prevalence of chronic diseases is accelerating demand for personalized medicine biomarkers.

Companies in the personalized medicine biomarkers market are focusing on obtaining regulatory approvals to enhance product credibility, expand their market reach, and improve patient outcomes. Regulatory approvals are essential as they ensure that medical products, treatments, or technologies meet safety, efficacy, and quality standards. For instance, in August 2024, Illumina, Inc., a US-based biotechnology company, received FDA approval for its cancer biomarker test and two companion diagnostics. The test uses next-generation sequencing (NGS) technology to identify genetic mutations in cancer cells, allowing clinicians to select the most appropriate treatments based on individual biomarkers. This approval represents a significant milestone in precision oncology, improving the speed and accuracy of treatment selection and enhancing personalized care for cancer patients.

In February 2025, Renovaro Inc., a US-based biotechnology firm, merged with BioSymetrics Inc. to boost AI-driven biomarker discovery and precision medicine initiatives. The merger is set to enhance drug development and facilitate the creation of personalized treatment strategies, particularly for complex diseases. BioSymetrics Inc., a Canada-based company specializing in phenomics-driven drug discovery, uses machine learning to integrate clinical and experimental data, advancing the field of precision medicine.

Major players in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

North America was the largest region in the personalized medicine biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in personalized medicine biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the personalized medicine biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The personalized medicine biomarkers market consists of sales of biomarker-based diagnostic kits, reagents, testing platforms, epigenetic biomarkers, companion diagnostics, predictive biomarkers, prognostic biomarkers, and multi-omics biomarkers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Personalized Medicine Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on personalized medicine biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for personalized medicine biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The personalized medicine biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Personalized Medicine Biomarkers Market Characteristics

3. Personalized Medicine Biomarkers Market Trends And Strategies

4. Personalized Medicine Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Personalized Medicine Biomarkers Growth Analysis And Strategic Analysis Framework

6. Personalized Medicine Biomarkers Market Segmentation

7. Personalized Medicine Biomarkers Market Regional And Country Analysis

8. Asia-Pacific Personalized Medicine Biomarkers Market

9. China Personalized Medicine Biomarkers Market

10. India Personalized Medicine Biomarkers Market

11. Japan Personalized Medicine Biomarkers Market

12. Australia Personalized Medicine Biomarkers Market

13. Indonesia Personalized Medicine Biomarkers Market

14. South Korea Personalized Medicine Biomarkers Market

15. Western Europe Personalized Medicine Biomarkers Market

16. UK Personalized Medicine Biomarkers Market

17. Germany Personalized Medicine Biomarkers Market

18. France Personalized Medicine Biomarkers Market

19. Italy Personalized Medicine Biomarkers Market

20. Spain Personalized Medicine Biomarkers Market

21. Eastern Europe Personalized Medicine Biomarkers Market

22. Russia Personalized Medicine Biomarkers Market

23. North America Personalized Medicine Biomarkers Market

24. USA Personalized Medicine Biomarkers Market

25. Canada Personalized Medicine Biomarkers Market

26. South America Personalized Medicine Biomarkers Market

27. Brazil Personalized Medicine Biomarkers Market

28. Middle East Personalized Medicine Biomarkers Market

29. Africa Personalized Medicine Biomarkers Market

30. Personalized Medicine Biomarkers Market Competitive Landscape And Company Profiles

31. Personalized Medicine Biomarkers Market Other Major And Innovative Companies

32. Global Personalized Medicine Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Personalized Medicine Biomarkers Market

34. Recent Developments In The Personalized Medicine Biomarkers Market

35. Personalized Medicine Biomarkers Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â